A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits

Atherosclerosis

Volumn 251, Issue , 2016, Pages 70-77

  Tissier, Florine ^a   Mallem, Yassine ^b   Goanvec, Christelle ^a   Didier, Romain ^a,e   Aubry, Thierry ^c   Bourgeois, Nathalie ^b   Desfontis, Jean Claude ^b   Dubreuil, Matthieu ^d   Le Grand, Yann ^d   Mansourati, Jacques ^a,e   Pichavant Rafini, Karine ^a   Plee Gautier, Emmanuelle ^e   Roquefort, Philippe ^c   Theron, Michael ^a   Gilard, Martine ^a,e  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b UPSP 5304 Laboratoire de Physiopathologie animale et de Pharmacologie fonctionnelle   (France)

^c ENSTA BRETAGNE   (France)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Elasticity; Elastin; Low dose; PWV; Statin; Vasoreactivity; Vessels

Indexed keywords

ATORVASTATIN; COLLAGEN; ELASTIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; BLOOD VESSEL ELASTICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELASTICITY; HEART RATE; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; MALE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PULSE WAVE; VASCULAR SMOOTH MUSCLE; AGING; ANIMAL; AORTA; ARTERY; BLOOD PRESSURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; LEPORIDAE; MECHANICAL STRESS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TENSILE STRENGTH; YOUNG MODULUS;

AGING; ANIMALS; AORTA; ARTERIES; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; BLOOD PRESSURE; COLLAGEN; DISEASE MODELS, ANIMAL; ELASTIC MODULUS; ELASTIN; HEART RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PULSE WAVE ANALYSIS; RABBITS; STRESS, MECHANICAL; TENSILE STRENGTH;

EID: 84973174677     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.05.039     Document Type: Article

References (50)

1. Stone N.J., Robinson J.G., Lichtenstein A.H., Merz C.N.B., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W.F. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation 2014, 129:S1-S45. 10.1161/01.cir.0000437738.63853.7a.
2. Makris G.C., Lavida A., Nicolaides A.N., Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins?. Atherosclerosis 2010, 213:8-20. 10.1016/j.atherosclerosis.2010.04.032.
3. Amarenco P., Labreuche J., Lavallée P., Touboul P.-J. Statins in stroke prevention and carotid atherosclerosis systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909. 10.1161/01.STR.0000147965.52712.fa.
4. Blum A. HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis. BioFactors 2014, 40:295-302. 10.1002/biof.1157.
5. Satoh M., Takahashi Y., Tabuchi T., Minami Y., Tamada M., Takahashi K., Itoh T., Morino Y., Nakamura M. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin. Sci. 2015, 129:93-105. 10.1042/CS20150027.
6. Owens A.P., Mackman N. The antithrombotic effects of statins. Annu. Rev. Med. 2014, 65:433-445. 10.1146/annurev-med-051812-145304.
7. Antonopoulos A.S., Margaritis M., Lee R., Channon K., Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 2012, 18:1519-1530. 10.2174/138161212799504803.
8. Murrow J.R., Sher S., Ali S., Uphoff I., Patel R., Porkert M., Le N.-A., Jones D., Quyyumi A.A. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J. Clin. Lipidol. 2012, 6:42-49. 10.1016/j.jacl.2011.08.006.
9. Bruckert E., Ferrières J. Evidence supporting primary prevention of cardiovascular diseases with statins: gaps between updated clinical results and actual practice. Arch. Cardiovasc. Dis. 2014, 107:188-200. 10.1016/j.acvd.2014.01.011.
10. Libby P., Aikawa M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol. 2003, 91:4-8. 10.1016/S0002-9149(02)03267-8.
11. de Jongh S., Lilien M.R., op't Roodt J., Stroes E.S., Bakker H.D., Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 40:2117-2121. 10.1016/S0735-1097(02)02593-7.
12. Pasternak R.C., Smith Sidney C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins12. J. Am. Coll. Cardiol. 2002, 40:567-572. 10.1016/S0735-1097(02)02030-2.
13. Russo M.W., Hoofnagle J.H., Gu J., Fontana R.J., Barnhart H., Kleiner D.E., Chalasani N., Bonkovsky H.L. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatol. Balt. Md 2014, 60:679-686. 10.1002/hep.27157.
14. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M.J., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207. 10.1056/NEJMoa0807646.
15. Westover M., Bianchi M.T., Eckman M.H., Greenberg S.M. Statin use following intracerebral hemorrhage: a decision analysis. Arch. Neurol. 2011, 68:573-579. 10.1001/archneurol.2010.356.
16. Shiomi M., Ito T. The watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. Atherosclerosis 2009, 207:1-7. 10.1016/j.atherosclerosis.2009.03.024.
17. Zipfel W.R., Williams R.M., Webb W.W. Nonlinear magic: multiphoton microscopy in the biosciences. Nat. Biotechnol. 2003, 21:1369-1377. 10.1038/nbt899.
18. Boulesteix T., Pena A.-M., Pagès N., Godeau G., Sauviat M.-P., Beaurepaire E., Schanne-Klein M.-C. Micrometer scale ex vivo multiphoton imaging of unstained arterial wall structure. Cytom. A 2006, 69A:20-26. 10.1002/cyto.a.20196.
19. Williams R.M., Zipfel W.R., Webb W.W. Interpreting second-harmonic generation images of collagen I fibrils. Biophys. J. 2005, 88:1377-1386. 10.1529/biophysj.104.047308.
20. Sevrain D., Dubreuil M., Dolman G.E., Zaitoun A., Irving W., Guha I.N., Odin C., Le Grand Y. Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis. Biomed. Opt. Express 2015, 6:1209-1218. 10.1364/BOE.6.001209.
21. Dirisamer A., Hachemian N., Bucek R.A., Wolf F., Reiter M., Widhalm P.K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur. J. Pediatr. 2003, 162:421-425. 10.1007/s00431-003-1181-3.
22. Tawakol A., Fayad Z.A., Mogg R., Alon A., Subramanian S., Abdelbaky A., Nunes I., Herman G., Beals C., Shankar S.S. Abstract 18242: high dose statin results in a further reduction in atherosclerotic inflammation compared with low dose statin: results of a multi-center PET-CT study. Circulation 2011, 124:A18242.
23. Kunt A., Özcan S., Küçüker A., Odabaşi D., Sami Kunt A. Efficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: low-dose versus high-dose. Med. Glas. Off. Publ. Med. Assoc. Zenica Doboj Cant. Bosnia Herzeg 2015, 12:196-201. 10.17392/795-15.
24. Laurent S., Cockcroft J., Bortel L.V., Boutouyrie P., Giannattasio C., Hayoz D., Pannier B., Vlachopoulos C., Wilkinson I., Struijker-Boudier H. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. Heart J. 2006, 27:2588-2605. 10.1093/eurheartj/ehl254.
25. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffnessa systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010, 55:1318-1327. 10.1016/j.jacc.2009.10.061.
26. Kanaki A.I., Sarafidis P.A., Georgianos P.I., Kanavos K., Tziolas I.M., Zebekakis P.E., Lasaridis A.N. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am. J. Hypertens. 2013, 26:608-616. 10.1093/ajh/hps098.
27. Gong X., Ma Y., Ruan Y., Fu G., Wu S. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp. Gerontol. 2014, 52:9-17. 10.1016/j.exger.2014.01.015.
28. Sander K., Hof U., Poppert H., Conrad B., Sander D. Improved cerebral vasoreactivity after statin administration in healthy adults. J. Neuroimaging 2005, 15:266-270. 10.1111/j.1552-6569.2005.tb00320.x.
29. Giannopoulos S., Katsanos A.H., Tsivgoulis G., Marshall R.S. Statins and cerebral hemodynamics. J. Cereb. Blood Flow. Metab. Off. J. Int. Soc. Cereb. Blood Flow. Metab. 2012, 32:1973-1976. 10.1038/jcbfm.2012.122.
30. Holowatz L.A., Santhanam L., Webb A., Berkowitz D.E., Kenney W.L. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans. J. Physiol. 2011, 589:2093-2103. 10.1113/jphysiol.2010.203935.
31. van Popele N.M., Grobbee D.E., Bots M.L., Asmar R., Topouchian J., Reneman R.S., Hoeks A.P.G., van der Kuip D.A.M., Hofman A., Witteman J.C.M. Association between arterial stiffness and atherosclerosis the rotterdam study. Stroke 2001, 32:454-460. 10.1161/01.STR.32.2.454.
32. Dobrynin A.V., Carrillo J.-M.Y. Universality in nonlinear elasticity of biological and polymeric networks and gels. Macromolecules 2011, 44:140-146. 10.1021/ma102154u.
33. Lunder M., Janić M., Habjan S., Šabovič M. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males - a pilot study. Atherosclerosis 2011, 215:446-451. 10.1016/j.atherosclerosis.2010.12.041.
34. Ballard K.D., Taylor B.A., Capizzi J.A., Grimaldi A.S., White C.M., Thompson P.D. Atorvastatin treatment does not alter pulse wave velocity in healthy adults. Int. Sch. Res. Not. 2014, 2014:e239575. 10.1155/2014/239575.
35. Assoul N., Flaud P., Chaouat M., Letourneur D., Bataille I. Mechanical properties of rat thoracic and abdominal aortas. J. Biomech. 2008, 41:2227-2236. 10.1016/j.jbiomech.2008.04.017.
36. Zhang J., Zhao X., Vatner D.E., McNulty T., Bishop S., Sun Z., Shen Y.-T., Chen L., Meininger G.A., Vatner S.F. Extracellular matrix disarray as a mechanism for greater abdominal versus thoracic aortic stiffness with aging in primates. Arterioscler. Thromb. Vasc. Biol. 2016, 36:700-706. 10.1161/ATVBAHA.115.306563.
37. Figueiredo J.-L., Aikawa M., Zheng C., Aaron J., Lax L., Libby P., de Lima Filho J.L., Gruener S., Fingerle J., Haap W., Hartmann G., Aikawa E. Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease. Am. J. Pathol. 2015, 185:1156-1166. 10.1016/j.ajpath.2014.11.026.
38. Wang J., Sjöberg S., Tang T.-T., Öörni K., Wu W., Liu C., Secco B., Tia V., Sukhova G.K., Fernandes C., Lesner A., Kovanen P.T., Libby P., Cheng X., Shi G.-P. Cathepsin G activity lowers plasma LDL and reduces atherosclerosis. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2014, 1842:2174-2183. 10.1016/j.bbadis.2014.07.026.
39. Karimi A., Navidbakhsh M., Shojaei A. A combination of histological analyses and uniaxial tensile tests to determine the material coefficients of the healthy and atherosclerotic human coronary arteries. Tissue Cell 2015, 47:152-158. 10.1016/j.tice.2015.01.004.
40. Dalessandri K.M., Eisele P., Wong T.S., Parker J., Rucker R.B. Elastin degradation in the aorta of Watanabe hereditary hyperlipidemic rabbits. Mech. Ageing Dev. 1994, 74:117-120. 10.1016/0047-6374(94)90103-1.
41. Abisi S., Burnand K.G., Humphries J., Waltham M., Taylor P., Smith A. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br. J. Surg. 2008, 95:333-337. 10.1002/bjs.5989.
42. Briones A.M., Rodríguez-Criado N., Hernanz R., García-Redondo A.B., Rodrigues-Díez R.R., Alonso M.J., Egido J., Ruiz-Ortega M., Salaices M. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009, 54:142-149. 10.1161/HYPERTENSIONAHA.109.133710.
43. Blankier S., McCrindle B.W., Ito S., Yeung R.S.M. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin. Exp. Immunol. 2011, 164:193-201. 10.1111/j.1365-2249.2011.04331.x.
44. Krishna S.M., Seto S.W., Jose R.J., Biros E., Moran C.S., Wang Y., Clancy P., Golledge J. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2015, 35:389-398. 10.1161/ATVBAHA.114.304732.
45. Redondo S., Santos-Gallego C.G., Tejerina T. TGF-β1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev. 2007, 18:279-286. 10.1016/j.cytogfr.2007.04.005.
46. Redondo S., Santos-Gallego C.G., Ganado P., García M., Rico L., Rio M.D., Tejerina T. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β. Circulation 2003, 107:626-629. 10.1161/01.CIR.0000045664.75269.A5.
47. Ip J.H., Fuster V., Badimon L., Badimon J., Taubman M.B., Chesebro J.H. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol. 1990, 15:1667-1687. 10.1016/0735-1097(90)92845-S.
48. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., Shiomi M., Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001, 103:993-999. 10.1161/01.CIR.103.7.993.
49. Santos-Gallego C.G., Giannarelli C., Badimón J.J. Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. Curr. Atheroscler. Rep. 2011, 13:266-276. 10.1007/s11883-011-0177-0.
50. Santos-Gallego C.G., Badimon J.J., Rosenson R.S. Beginning to understand high-density lipoproteins. Endocrinol. Metab. Clin. North Am. 2014, 43:913-947. 10.1016/j.ecl.2014.08.001.